In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Guilford sells Merck's Aggrastat in the US

Executive Summary

CNS disease therapeutics company Guilford Pharmaceuticals paid $84mm cash for the exclusive US rights (including Puerto Rico, Guam, and the Virgin Islands) to sell Merck's Aggrastat (tirofiban hydrochloride) injection for platelet-mediated cardiovascular disease. In addition, it pays royalties on net sales until December 2012.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)
    • Reverse Licensing

Related Companies